• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » General Electric slips despite Q2 earnings beat, raised outlook

General Electric slips despite Q2 earnings beat, raised outlook

July 31, 2019 By Brad Perriello

General ElectricGeneral Electric (NYSE:GE) shares took a hit today after the industrial conglomerate missed the consensus forecast for its second-quarter sales, despite topping the earnings forecast and raising its outlook on the rest of the year.

Boston-based GE posted losses of -$61.0 million, or -1¢ per share, on sales of $26.79 billion for the three months ended June 30, swinging to red ink on a -1.3% sales decline compared with Q2 2018. Adjusted to exclude one-time items, earnings per share were 17¢, a full nickel ahead of Wall Street, where analysts were looking for revenues of $28.68 billion.

“We made steady progress on our strategic priorities in the second quarter. Our top-line growth was solid, and power made meaningful improvements on fixed cost reduction and project execution. Margins contracted due to declines in power, renewable energy, and to a lesser extent aviation, with the first half of 2019 in line with our full-year outlook. We also moved our grid solutions equipment and services business to renewable energy to offer end-to-end clean energy solutions and moved our grid solutions software business to digital, which resulted in a non-cash goodwill impairment charge,” chairman & CEO Lawrence Culp Jr. said in prepared remarks. “Due to improvements at power, lower restructuring and interest, higher earnings, and better visibility at the half, we are raising our full-year outlook for industrial segment organic revenues, adjusted EPS and industrial free cash flows, and we are holding our margin guidance. We will continue to take planned actions to improve our businesses and monitor some market headwinds, and we remain focused on driving continuous improvement and delivering for our customers. I am encouraged by our team’s progress and dedication to date.”

GE said it now expects to put up adjusted EPS of 55¢ to 65¢ this year, up from 50¢ to 60¢ previously.

Still, investors sent GE shares down -1.2% to $10.40 apiece today in mid-day activity.

Healthcare profits rise despite flat sales

Profits for GE Healthcare grew 3.5% to $958.0 million on a -0.9% sales decline to $4.93 billion. GE said the profit gain was driven by “volume and cost productivity, partially offset by inflation, tariffs, and program investments.”

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: GE Healthcare, General Electric

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy